Fig. 2

Rab25 expression increases cisplatin resistance of the human ovarian cancer cell line A2780. a Cell extracts were analysed by Western Blot to verify the expression of Rab25 after selection with geneticin. Tubulin expression was used as loading control. b The in vitro cytotoxicity of cisplatin was compared in the empty-vector expressing A2780 and Rab25-expressing A2780 by MTT assay. IC₅₀ is defined as the concentration of drug required to inhibition of cell growth by 50 %. c and d The in vivo cytotoxicity of cisplatin was analysed for seven days by caliper measurements in either A2780 (c) or A2780-Rab25 (d) s.c. xenografts following a single dose of cisplatin at its maximal tolerated dose (6 mg/Kg). e Graphical representation of relative doubling time of A2780 and A2780-Rab25 s.c. xenografts depicting time required for cisplatin-treated xenografts to reach same size as control. p<0.05, calculated by t-test